Abstract
This paper examines the role played by targeted funding in advancing research on a recalcitrant problem. A synoptic view of American studies of unexpected deaths of sleeping babies reveals two principal advances — (1) the establishment between 1945 and 1961 of sudden infant death `syndrome' as a problem for biomedical research, and (2) the recognition between 1969 and 1980 that many of the victims had congenital breathing abnormalities. Analysis of targeted federal funding shows that it played a lagging rather than leading role in both major advances. That is, while such funds provided little support for the initial insights, they fostered much of the follow-up work. A few suggestions about how funding agencies might handle significant yet recalcitrant problems are offered by way of conclusion.
Get full access to this article
View all access options for this article.
